
Novartis is planning to unify the two manufacturing plants used by Sandoz unit Fougera Pharmaceuticals in the US, expanding and …

Novartis will acquire the dermatology generics firm Fougera for $1.53 billion in cash. Novartis’ generic unit Sandoz is conducting the …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

